N-benzyl-tropin-4-ol | 3804-68-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-benzyl-tropin-4-ol
• 英文别名: N-Benzyl-norpseudotropin；N-Benzyl-nortropanol-(3α)；N-Benzyl-nortropan-3β-ol；N-Benzyl-nortropan-3α-ol；8-benzyl-8-aza-bicyclo[3.2.1]octan-3-ol；8-benzyl-nortropan-3-ol；8-Benzyl-8-azabicyclo[3.2.1]octan-3-ol
• CAS: 3804-68-0
• 化学式: C₁₄H₁₉NO
• mdl: MFCD09966164
• 分子量: 217.311
• InChiKey: HCBGIBWAPOFRKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  N-benzyl-tropin-4-ol 在 potassium carbonate 、 三乙胺 、 红铝 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 23.0h， 生成 3-(1-Benzyl-tropin-4-yl)-5,5-diphenyl-imidazolidin-2-one
  参考文献：
  名称：

  Discovery of Diaryl Imidazolidin-2-one Derivatives, a Novel Class of Muscarinic M3 Selective Antagonists (Part 1)

  摘要：

  Pharmacophore-based structural identification, synthesis, and structure-activity relationships of a new class of muscarinic M3 receptor antagonists, the diaryl imidazolidin-2-one derivatives, are described. The versatility of the discovered scaffold allowed for several structural modifications that resulted in the discovery of two distinct classes of compounds, specifically a class of tertiary amine derivatives (potentially useful for the treatment of overactive bladder by oral administration) and a class of quaternary ammonium salt derivatives (potentially useful for the treatment of respiratory diseases by the inhalation route of administration). In this paper, we describe the synthesis and biological activity of tertiary amine derivatives. For these compounds, selectivity for the M3 receptor toward the M2 receptor was crucial, because the M2 receptor subtype is mainly responsible for adverse systemic side effects of currently marketed muscarinic antagonists. Compound 50 showed the highest selectivity versus M2 receptor, with binding affinity for M3 receptor K-i = 4.8 nM and for M2 receptor K-i = 1141 nM. Functional in vitro studies on selected compounds confirmed the antagonist activity toward the M3 receptor and functional selectivity toward the M2 receptor.

  DOI：

  10.1021/jm061159a
• 作为产物：
  描述：

  N-苄基托品酮 在 L-Selectride 、 sodium hydroxide 、 双氧水 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.5h， 生成 N-benzyl-tropin-4-ol
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY
  [FR] NOUVEAUX COMPOSES PRESENTANT UNE ACTIVITE ANTIBACTERIENNE

  摘要：

  本发明描述了具有通式(I)的新型抗菌化合物。这些化合物在其他方面，尤其是作为DNA促旋酶抑制剂，具有研究价值。

  公开号：

  WO2006021448A1

文献信息

• [EN] CHEMOKING RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE CHIMIOKINES
  申请人：ABBOTT LAB

  公开号：WO2013010453A1

  公开（公告）日：2013-01-24

  Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

  本文揭示了化学受体拮抗剂的化学式(I)，其中G1、X1、X2和X3如规范中所定义。还描述了包含这种化合物的组合物；以及使用这种化合物和组合物治疗疾病和疾病的方法。
• [EN] HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] DÉRIVÉS HÉTÉROARYLE POUR LE TRAITEMENT DE MALADIES RESPIRATOIRES
  申请人：CHIESI FARMA SPA

  公开号：WO2015082616A1

  公开（公告）日：2015-06-11

  The invention relates to novel compounds of formula (I) which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

  本发明涉及一种新型化合物，其化学式为(I)，既是磷酸二酯酶4（PDE4）酶抑制剂又是肌碱M3受体拮抗剂，以及制备这种化合物的方法、含有它们的组合物以及其治疗用途。
• [EN] DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY<br/>[FR] COMPOSES DIAMIDES AYANT UN ANTAGONISTE DU RECEPTEUR MUSCARINIQUE ET UNE ACTIVITE AGONISTE DES RECEPTEURS ADRENERGIQUES BETA2
  申请人：THERAVANCE INC

  公开号：WO2010123766A1

  公开（公告）日：2010-10-28

  This invention relates to a compound of formula I; or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.

  这项发明涉及公式I的化合物；或其药学上可接受的盐。这些化合物具有毛细血管收缩受体拮抗剂和β2肾上腺素受体激动剂活性。该发明还涉及包含这些化合物的药物组合物、制备这些化合物的过程和中间体，以及将这些化合物用作支气管扩张剂治疗肺部疾病的方法。
• [EN] INDOLYLPYRIMIDINES AS MODULATORS OF GPR119<br/>[FR] COMPOSÉS INDOLYLPYRIMIDINES EN TANT QUE MODULATEURS DE GPR119
  申请人：LUPIN LTD

  公开号：WO2012025811A1

  公开（公告）日：2012-03-01

  The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions modulated by GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR119 receptor by using either alone or in combinations of Formula (I).

  本发明涉及一种化合物（I）的公式，该化合物对于治疗、预防和/或管理由GPR119受体活性调节的疾病、紊乱、综合征或病况是有用的。该发明还涉及制备这些化合物的方法、其药物组合物。此外，该发明还涉及利用单独或以公式（I）的组合物治疗、预防和/或管理与GPR119受体调节相关的疾病、紊乱、综合征或病况的方法。
• HETEROARYL DERIVATIVES
  申请人：CHIESI FARMACEUTICI S.P.A.

  公开号：US20150158858A1

  公开（公告）日：2015-06-11

  Compounds of formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

  本文描述的化合物（I）的化学式既是磷酸二酯酶4（PDE4）酶抑制剂，又是毒蕈碱M3受体拮抗剂，可用于预防和/或治疗呼吸道疾病，其特征是气道阻塞。